HIV/AIDS remains a major health care problem both in the U.S. and throughout the world. The long term goals of the Miami Clinical Trials Unit (CTU), as a member of the AIDS Clinical Trials Group (ACTG) and as an applying member for the HIV Vaccine Treatment Network (HVTN), are to arrest and reverse human immunodeficiency virus (HIV) disease and to prevent infection through vaccine development, with the ultimate objective of curing and preventing HIV. To achieve these goals, we propose to continue our 19 year affiliation with the ACTG Network and to expand our efforts into the high priority area of Vaccine Research Development with the HVTN Network. The Miami CTU brings together investigators with broad and long standing experience in the design and conduct of therapeutic HIV clinical studies, vaccine studies, in prevention behavioral studies, and in the development, evaluation and implementation of immunologic and virologic parameters for the assessment of therapeutic and prevention interventions. The Miami CTU proposes a fully integrated Administrative Core and Clinical Research Site, the University of Miami AIDS Clinical Research Unit (UM ACRU), and therefore will also bring a currently functioning research facility with long-standing expertise and the ability to identify, recruit and follow an infected population and a high risk population for the acquisition of HIV that includes women, minority patients, and injection drug users. With 20 years experience in assessing and following at risk individuals for HIV infection, and the long standing experience and expertise in therapeutic clinical trials, the Miami CTU brings the flexibility and capability to conduct multiple clinical research projects in all phases of development with the ability to rapidly respond to evolving and innovative research. A major strength of the Miami CTU is its proven design, implementation and follow-up capabilities in therapeutic clinical trials. The Miami CTU will continue to contribute and expands its efforts in the treatment and prevention of HIV by: leadership in the design and conduct of HIV-1 clinical studies;actively contributing to the scientific agenda of the ACTG and the HVTN;maintain an average monthly census of 20 study participates over a 12-month period in each clinical trials area of the ACTG and HVTN;provide an expanded clinical capacity to recruit, screen, enroll, and follow no less than 100 study participants over a 12-month period in each clinical trials areas of the ACTG and HVTN;and work with and educate those at risk for HIV and those infected in South Florida. The proposed clinical trials and investigations will advance our understanding of the treatment and pathogenesis of HIV/AIDS, and lead to improved care and prevention of HIV. ADMINISTRATIVE COMPONENT:

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LD-A (M1))
Program Officer
Castillo, Blanca E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Miami School of Medicine
Internal Medicine/Medicine
Schools of Medicine
Coral Gables
United States
Zip Code
Lennox, Jeffrey L; Landovitz, Raphael J; Ribaudo, Heather J et al. (2014) Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 161:461-71
Leger, Paul D; Johnson, Daniel H; Robbins, Gregory K et al. (2014) Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J Neurovirol 20:304-8
Johnson, Daniel H; Venuto, Charles; Ritchie, Marylyn D et al. (2014) Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 24:195-203
Jacobson, Jeffrey M; Wang, Hongying; Bordi, Rebeka et al. (2014) A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr 66:399-406
Bronke, Corine; Almeida, Coral-Ann M; McKinnon, Elizabeth et al. (2013) HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. AIDS 27:899-905
Ribaudo, Heather J; Daar, Eric S; Tierney, Camlin et al. (2013) Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis 207:420-5
Hogan, Christine M; Degruttola, Victor; Sun, Xin et al. (2012) The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 205:87-96